Dyne Therapeutics (DYN) Receives a Buy from Morgan Stanley

In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics, with a price target of $48.00. The company’s shares closed yesterday at $12.65.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Ulz covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Rhythm Pharmaceuticals, and Alnylam Pharma. According to TipRanks, Ulz has an average return of 2.4% and a 42.64% success rate on recommended stocks.

In addition to Morgan Stanley, Dyne Therapeutics also received a Buy from Piper Sandler’s Edward Tenthoff in a report issued on September 29. However, on September 25, BMO Capital assigned a Hold rating to Dyne Therapeutics (NASDAQ: DYN).

The company has a one-year high of $35.90 and a one-year low of $6.36. Currently, Dyne Therapeutics has an average volume of 2.75M.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DYN in relation to earlier this year. Most recently, in July 2025, John Cox, the CEO & President of DYN bought 100,000.00 shares for a total of $911,000.00.